DBV Technologies expands its scientific advisory board
This article was originally published in Scrip
DBV Technologies (France), a biopharmaceutical company focused on the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, has expanded its scientific advisory board with the appointments of Professor Gideon Lack and Associate Professor Philippe Eigenmann. Professor Lack is head of the children’s allergy service at Guy's and St Thomas' NHS Foundation Trust and a professor of paediatric allergy at King's College, London, while Professor Eigenmann is an associate professor at the department of infants and adolescents at the Hospital cantonal Universitaire Genève, Switzerland, specialising in paediatric allergy diagnosis and treatment.
You may also be interested in...
A study of drug approvals over more than three decades shows antimicrobials, including antibacterials, had consistently shorter development and review times than other types of products. While antibacterials were less likely to participate in special US FDA programs designed to help along review, experts said reimbursement reform, not new regulatory flexibility, is needed to help address the crisis of drug-resistant infections.
US FDA commissioner Stephen Hahn emphasized the important role that telemedicine, COVID-19 testing, and agency-reviewed face masks and ventilators have played during the pandemic in a 1 June speech.
Zimmer Biomet has agreed to pay $9.6m to Conformis Inc. to resolve a dispute over personalized joint replacement technology.